TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06335355: A Phase II/III, Randomized, Open-label, Parallel-controlled, Multicenter Study of Adebrelimab (SHR-1316) in Combination With SHR-8068 and Platinum-based Doublet Chemotherapy as First-line Treatment in Advanced or Metasta

Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 401 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT06335355 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06335355 Rescue Dossier →